A randomized, double-blind, placebo-controlled, crossover study evaluated the effects of [Pyr1]-apelin-13 in 24 subjects (12 patients with chronic kidney disease (CKD) and 12 matched healthy controls). Here, APLN is linked to chronic kidney disease.